Thermo Fisher Scientific Inc
LSE:0R0H
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178.5B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
947.7B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
133.8B USD |
Loading...
|
|
| DE |
|
Merck KGaA
XETRA:MRK
|
46.6B EUR |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.6B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.4B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
266.5B CNY |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Thermo Fisher Scientific Inc
Glance View
Thermo Fisher Scientific Inc. stands as a towering entity in the life sciences industry, intricately weaving together science, technology, and business to drive scientific progress and innovation. Founded through a merger of Thermo Electron and Fisher Scientific in 2006, the company has grown exponentially to become a formidable partner for researchers, academicians, and clinicians worldwide. Its business model is built around a broad portfolio of offerings, including laboratory instruments, analytical tools, and consumables, which are crucial for research and quality control. By emphasizing research and development, Thermo Fisher has consistently advanced its technologies, ensuring that its solutions remain indispensable to ventures in pharmaceuticals, biotechnology, and diagnostics. The strategic acquisition of complementary businesses has been a key facet of Thermo Fisher’s growth, fortifying its position across various scientific fields. In essence, the company thrives on understanding the increasingly complex demands of the scientific community. It generates revenue by capitalizing on its diverse product lineup, subscription-based services, and personalized solutions that cater to specific client needs—ranging from equipment used to perform intricate genomic sequencing to reagents required for advanced laboratory experiments. Thus, Thermo Fisher sustains its financial health through a combination of one-time sales and recurring revenue streams, a strategy that not only reflects its adaptability but also ensures long-term profitability and market leadership in the ever-evolving landscape of scientific research.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Thermo Fisher Scientific Inc is 15%, which is above its 3-year median of 14.4%.
Over the last 3 years, Thermo Fisher Scientific Inc’s Net Margin has decreased from 15.5% to 15%. During this period, it reached a low of 13.1% on Jul 1, 2023 and a high of 15.5% on Dec 31, 2022.